Skye Bioscience, Inc. (NASDAQ:SKYE) is making waves in the biopharmaceutical industry with its innovative approach to obesity treatment. The company's lead candidate, nimacimab, a CB1 negative ...

YOU might be full to bursting with food but, somehow, there’s always room for dessert. Your cravings for a sugar don’t mean you’re greedy – in fact, wanting a sweet treat ...

IVIEW Therapeutics Inc., a clinical-stage biotechnology company dedicated to advancing innovative treatments for ocular diseases, today announced positive topline data from its Phase 1/2 clinical ...

Netflix’s action movie selection is so stacked, it’s a cinematic adrenaline shot. Even if you don’t typically go for high-octane thrills, there's something on offer that'll have you gripping ...

New research suggests that δ-receptor agonists regulate intestinal motility ... indicating the compound’s selective action on stress-induced intestinal dysfunction. In the Capsaicin-Induced ...

The researchers found that both SGLT2 inhibitors and GLP-1 agonists were associated with a lower risk of major cardiovascular events, but the drug effects varied with the patients’ age.

Intercontinental Exchange and RELX are among the stocks that are now expensive. We sell different types of products and services to both investment professionals and individual investors. These ...

There’s a reason that the most successful genre on the home market has been the same for over a generation now: People love action movies. They allow us to escape reality and enter a world where ...

Currently, there are two approved GLP-1 and one combined GIP/ GLP-1 receptor agonists indicated for chronic weight management. The advent of these treatments not only provide a vital tool in the ...

Glucagon-Like Peptide-1 Agonists (GLP-1s) Glucagon-like peptide-1 agonists (GLP-1s) can increase the release of insulin when blood sugar is rising and help with weight loss by making you feel full ...

Excluding people with type 2 diabetes from the trial might have resulted in a missed opportunity to establish whether people with both Parkinson's disease and type 2 diabetes could benefit from GLP-1 ...